Multicell Technology inc Pre-Phase one potential lawsuit.
This is an exploratory investigation for a potential lawsuit to see if there are enough interested investors to support a lawsuit for neglect of fiduciary duties and responsibilities.
If this becomes a suit, this won't cost you any money.
The nationally known attorney asked me (mcetdreamer) to do some leg work . They are considering a couple different ways of pursuing this case, including a class action suit? This is why we need your help and information.
I am not an attorney, I don't have a crystal ball and I have no idea how they're going to proceed or even if they will.
Don't count your eggs before they are not hatched.
They would like to know your name, how many shares you own, contact information, including your address, phone.
Please keep it short, you can add any information that you feel is important. But it would be best to also copy me at my email: mcetdreamer@gmail.com if you have any questions? And I will try to get back with you or post it on I-HUB for all to see. But at this point, it most likely too early to help answer any questions.
Your information will be kept confidential, organized by Dan Brinkman.
Dan posted the MCET YouTube presentation a couple of months ago. He also has been working on several other spreadsheets. Dan is also a stockholder offering his services for free. Once everything is documented, your information will added with other investors on a spreadsheet and sent directly to the attorney to evaluate. Then they will contact you if and only if they feel there are enough interested investors and they decide to go with a class action suit?
There aren't any restrictions that I know of.
Anyone that sends their information to this email below:
mcetprephaseone@gmail.com
Your information will be sent to the attorney. No if and and butts. I would assume you would eventually need to show proof? Also they would like to know if you lost any money. But it not a necessity.
This is a real exploratory investigation and if you read my due diligence? You know there is Merritt for potential cases. You will also know there are many companies Infringing on the Fa N2-4 Immortalized human hepatocytes cell lines patent.
One company called Sekisui Xenotech has 18 distributors around the world that sells the Fa N2-4 cell line without paying a dime to Multicell Technologies Inc. In 2006 MCET terminated Xenotech contract for not paying $18,000,000 plus 3% royalties. Sekisui bought Xenotech about 2008.
JCRB is another company that is Infringing on this patent. They are based in Japan and manufacturers up to 1600 different Fa N2-4 Immortalized human hepatocytes cell lines.
Please see one of my posts below of hundreds.
Mcetdreamer Friday, 02/19/21 10:34:33 AM
Re: Mcetdreamer post# 44455 0
Post #
45101
of 49873
1) PAID IN FULL MCET's Patent Maintenance Fee on 12-18-2020 for their Fa 2N-4 and Ea1C-35 Immortalized Human Hepatocytes Cell Lines
Please read below 5) to see how many companies and universities that are infringing on MCETs Patent with paying Multicell Technology Inc
U.S.P.T.O.Maintenance Fee Storefront Link:
fees.uspto.gov
IMMORTALIZED HEPATOCYTES
PATENT #
7566567
APPLICATION #
10574163
FILING DATE
03/29/2006
ISSUE DATE
07/28/2009
Payment Window Status
WINDOW
11.5 Year
STATUS
Closed
FEES
Paid
Window
First Day to Pay
Surcharge Starts
Last Day to Pay
Status
Fees
Statement
3.5 Year 07/28/2012 01/29/2013 07/29/2013 Closed Paid Statement
7.5 Year 07/28/2016 01/31/2017 07/28/2017 Closed Paid Statement
11.5 Year 07/28/2020 01/29/2021 07/28/2021 Closed Paid Statement
Patent Holder Information
Customer # 87008
Entity Status UNDISCOUNTED
Phone Number (408) 993-1800
Address MultiCell Technologies, Inc.
c/o David Lewis
1250 Aviation Avenue, Suite 200B
San Jose, CA 95110
UNITED STATES
2)
MCET's patent attorney David Lewis is the original attorney on record that filed the Immortalized Hepatocytes patent for MCET with the US Patent Office
FILING DATE
03/29/2006
ISSUE DATE
07/28/2009
Recently, MCET patent attorney Mr David Lewis paid the maintenance fee on 12-18-2020 for MCET immortalized Human Hepatocytes cell lines
This is the same Fa 2N-4 immortalized human hepatocytes cell line patent that multiple companies and universities have been infringing on for years without having a license agreement or paying any kind of royalties to MCET.
In fact, XenoTech had a contract to pay MCET $18,000,000 plus 3% of the revenue and then decided to terminate the contract. But come to find out they are still using this same cell line and also licensing Fa 2N-4 themselves without any agreement with MCET or without paying a dime for them infringing on their Patent.
3)
Click on the website below that shows MCET Fa 2N-4 cell line is still being sold by SEKISUI XENOTECH: (December 2020:)
SEKISUI XENOTECH WEBSITE:
xenotech.com
4)
2005 article showing relationship between MCET and XenoTech and other companies.
Click on link below to read full article:
businesswire.com
MultiCell Develops Improved Cell Culture Media Supplement, MFE Supplement A; Four Immortalized Hepatocyte Posters presented at ISSX
October 28, 2005 09:48 AM Eastern Daylight Time
LINCOLN, R.I.--(BUSINESS WIRE)--Oct. 28, 2005--MultiCell Technologies, Inc. (OTCBB: MCET) announced today that XenoTech LLC, MultiCell's marketing and manufacturing licensee, introduced an improved cell culture media supplement called MFE Supplement A on October 25th at the joint ISSX / JSSX Meeting in Hawaii and presented latest data on the cell line and media with a scientific poster presentation.
MultiCell's new exclusive culture media supplement enhances the sensitivity of the cells to detect CYP3A4 inducers, which improves the ability of the cells to detect those drug candidates that have a high potential to cause certain types of drug-drug interactions.
“Improving the dynamic range of CYP3A4 induction in immortalized human hepatocytes (Fa2N-4 cells)”
MultiCell's progenitor cells and immortalized liver cells are used by XenoTech, Pfizer, Bristol Myers Squibb and a growing number of other pharmaceutical companies to improve the safety profile of drugs by identifying early in the drug development program those drug candidates that can cause clinically significant enzyme induction and drug-drug interactions. The cells are available in a variety of formats (cryopreserved or ready to use plates) for testing drug candidates to help lower drug development costs and help prevent costly drug recalls. In June, MultiCell announced sales of its immortalized human hepatocytes (Fa2N-4 cells) in shrink-wrapped vials and plates, allowing purchase of cells without no-grow agreements. By opening the wrap, a user indicates acceptance of the no-grow terms of a one-time use license. The companies now recommend, for best results, ordering a complete package of hepatocytes, culture media, and supplement A. Call XenoTech at 1 (913) GET- P450 and ask for the current special package promotional offer.
5)
Published: 18 October 2016
Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes
Methods Cell culture and labeling
Fa2N-4 cells (an immortalized normal hepatocyte cell line) were purchased from Xenotech (Lenexa, KS, USA), and Huh7, Hep3B, PLC/PRF/5, SNU475 and SNU449 (human hepatocellular carcinoma cell line) were obtained from the Korean Cell Line Bank (KCLB). Huh7.5 [14] was kindly provided by Charles M. Rice (Rockefeller University, New York, USA), and Huh6 [15] was kindly provided by Dr. Ralf Bartenschlager (University of Heidelberg, Germany). Cells were maintained at 37 °C with 95 % humidity and 5 % CO2. After cell attachment (3–6 h), serum-containing plating medium (XenoTech, Lenexa, KS, USA) was replaced with MFE serum free supporting Fa2N-4 cells (SF) medium (XenoTech) which are nutrient rich medium for maintaining Fa2N-4 cells in culture. This is a serum free medium. Huh7 cells (a human HCC cell line) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Gaithersburg, MD, USA) supplemented with heat-inactivated 10 % fetal bovine serum (FBS; Gibco) and antibiotics (Gibco) at 37 °C in a humidified incubator under 5 % CO2. For the 3D culture, 8 µl of Matrigel (BD Biosciences, San Jose, CA, USA) was pipetted directly onto the surface and carefully spread to avoid bubbles in 384 well culture plates (Greiner Bio-One, Monroe, NC, USA), then incubated at 37 °C until the Matrigel solidified. Trypsinized single cells from a monolayer were centrifuged at 1,000 rpm, resuspended in 30 ml of supporting culture medium, and plated onto the Matrigel-coated plates at a density of 2?×?103 cells/well. Cells were incubated for 30 min at 37 °C to settle onto the Matrigel, then 10 % Matrigel-Medium was slowly added to each well. After maintaining for 5 days, the Matrigel-Medium was replaced every 2 days.
Click on the link below for 2016 that shows multiple companies and Universities still use MCETs Patent.
bmccancer.biomedcentral.com
6)
I would hope now, since MCET is finally having their Patent attorney pay this maintenance fee. That this would be a first step to go after everyone that has been infringing on all their parents
7)
MultiCell Technologies Inc., a Providence-based developer of therapeutics for the treatment of degenerative neurological diseases, has terminated the exclusive license agreement with XenoTech LLC of Kansas for "failure to meet minimum royalty obligations," according to company officials.
Link to article:
bizjournals.com
Hi Ed,
I was hoping to get it out ASAP.
We have about 17 Days before we talk to Timothy again. Then they they need at least a month after that. And since we are on a time crunch and I already waisted a week missing the meeting last week. Time isn't on our side.
I was hoping to send it out today or over the weekend.
I understand you don't have time. But I can work on this after work today.
It looks like Dan can't help with the spreadsheet. He contacted me but didn't offer to help.
I will set up a email address later today for them to send their information.
Rob
Show quoted text
I was going to start with I-hub to post this message? But I am sure we have a couple of options like that?
So, it doesn't need to be perfect? I am sure if someone read my posts. They know I am not the best writer.
Show quoted text
Show quoted text |
